We report that a lower PFS for MCLs compared to other BCLs and alloHCT did not seem to overcome the impact of high-risk disease features, since 75% of MCL with P53/TP53 expression/mutation and all patients with blastoid or pleomorphic morphology relapsed within 3 years. This evidence concerns the gene TP53 and mantle cell lymphoma.